Tofacitinib Shows Promise in Ulcerative Colitis

The JAK inhibitor induced and sustained remission at higher rates than placebo, although treatment was also linked to a higher rate of adverse events.

(RSS generated with FetchRss)

FULL ARTICLE: http://zpr.io/PFLgY